Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 9Carcinoma, Transitional Cell 6Carcinoma, Merkel Cell 6Breast Neoplasms 5Neoplasm Metastasis 4Carcinoma, Renal Cell 4Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Primary Myelofibrosis 1Penile Squamous Cell Carcinoma (PSCC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 56enzalutamide 44Specimen Handling 37apalutamide 35Androgen Antagonists 35Abiraterone Acetate 29Prednisone 27Radiosurgery 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 21Radiotherapy 21Leuprolide 20Biopsy 16relugolix 14acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 14gallium 68 PSMA-11 12Triptorelin Pamoate 12Surveys and Questionnaires 12Radiation 12Gonadotropin-Releasing Hormone 12X-Rays 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 10cabazitaxel 9bicalutamide 9Standard of Care 9Nivolumab 9Goserelin 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × avelumab × 90 days × Clear all
NCT04071236 2026-05-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

NCT03217747 2026-05-05

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
173 enrolled 28 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡